MRD Directed Therapeutic Decision Making in Multiple Myeloma
In this video, “MRD Directed Therapeutic Decision Making in Multiple Myeloma”, Sagar Lonial, MD, FACP, and Saad Usmani, MD, MBA, FACP, discuss the role of minimal residual disease in MM management.
The therapeutic landscape for multiple myeloma (MM) is complex, and it continues to evolve as more treatment options become available. Several clinical trials have reported data regarding the prognostic value of minimal residual disease (MRD). Interpreting this data is a challenge, and utilizing MRD to make treatment decisions remains controversial.